A Phase I/Ib Study of BP1002 (a Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BP 1002 (Primary) ; Decitabine (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Sponsors Bio-Path Holdings

18 Apr 2024 According to a Bio-Path Holdings media release, the company clinical trial will pause for a brief data review by the FDA, and then we expect that dose testing will continue at the next planned higher dose of 60 mg/m2.
18 Apr 2024 According to a Bio-Path Holdings media release, company announced completion of the second dose cohort of the dose escalation portion
02 Apr 2024 According to a Bio-Path Holdings media release, Enrollment is now open for patients for the second dose cohort of 40 mg/m2.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com